News
We send the latest information from SMC Laboratories.
Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse. Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…
CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstrating the efficacy of leronlimab (a CCR5 antagonist) in liver disease models. Using our STAM (MASH-HCC) and CCl₄-induced liver fibrosis models, leronlimab monotherapy successfully reversed liver fibrosis—an area with significant unmet medical need. These findings suggest that leronlimab’s anti-fibrotic…
Case study: Study published in Periodontitis promotes hepatocellular carcinoma Stelic Animal model mice.
We introduce a case study of basic research using our MASH model (STAM™ model). It has been reported that periodontal disease may aggravate hepatocellular carcinoma, but the detailed mechanism behind this was unknown. To clarify the relationship between periodontal disease and hepatocellular carcinoma, the authors induced periodontitis in STAM™ mice and examined how it…
CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC
CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. Resmetriom has been included in this pharmacology study, and its efficacy in treating fibrosis is directly compared with that of leronlimab. For detail information, see the CytoDyn’s press release. CytoDyn Announces Preliminary Findings in Study with…
Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.
We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (STAM™ model). The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis – Huang – 2024 – Clinical and Translational Science – Wiley Online Library In this paper,…
Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (November 15-19). For detailed information, see the below URL. aasld.org/sites/default/files/2024-10/1_the_liver_meeting_2024_abstracts.pdf Poster #1060 The beneficial effect of resmetirom on tumorigenesis associated with MASH in STAM mice Institution: Kurume University School of Medicine (Japan) Poster #1082 Impact…
Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and after conducting pre-clinical studies in mice at our company, submitted the results of their research to Nature Biotechnology. This article identifies TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic…
Preclinical HCC study with positive control, Lenvatinib
We recently obtained new evaluation data on the Lenvatinib in our STAM model and it shows significantly improving effects on the Number, Size and Growth Rate of the tumor nodules in the liver as well as on the overall survival. (Please see the data below) …
Enhance Research with Our Updated Model Lineup
We are introducing new disease models to our portfolio of preclinical mouse models. Our extensive lineup offers comprehensive support for your research. The new models in our lineup: Obesity type MASH/NASH-HCC; GAN diet model The GAN diet model is a frequently used model for studies on obesity type MASH. We included this model…
Results of Resmetirom fibrosis targeting study using STAM™ model
Recently, we have obtained the results of a study of resmetirom for the treatment of fibrosis using STAMTM-HCC/IO+ model, and would like to share them with you. Resmetirom treatment confirmed improvement of steatosis score, NAFLD Activity score and fibrosis resolution effects. Thus, the STAMTM-HCC/IO+ model has been shown to show similar improvements in…